The purpose of this study was to design and optimize a new topical delivery
system for ocular administration of flurbiprofen (FB), based on lipid
nanoparticles. These particles, called nanostructured lipid carriers (NLC), were
composed of a fatty acid (stearic acid (SA)) as the solid lipid and a mixture of
Miglyol®
812 and castor oil (CO) as the liquid lipids, prepared by the hot high pressure
homogenization method. After selecting the critical variables influencing the
physicochemical characteristics of the NLC (the liquid lipid (i.e. oil) concentration with
respect to the total lipid (cOil/L (wt%)), the surfactant and the flurbiprofen
concentration, on particle size, polydispersity index and encapsulation efficiency), a
three-factor five-level central rotatable composite design was employed to plan and
perform the experiments. Morphological examination, crystallinity and stability
studies were also performed to accomplish the optimization study. The results
showed that increasing cOil/L (wt%) was followed by an enhanced tendency to
produce smaller particles, but the liquid to solid lipid proportion should not exceed
30 wt% due to destabilization problems. Therefore, a 70:30 ratio of SA to oil (miglyol + CO) was selected to develop an optimal NLC formulation. The smaller particles
obtained when increasing surfactant concentration led to the selection of 3.2 wt% of
Tween®
80 (non-ionic surfactant). The positive effect of the increase in FB concentration
on the encapsulation efficiency (EE) and its total solubilization in the lipid
matrix led to the selection of 0.25 wt% of FB in the formulation. The optimal
NLC showed an appropriate average size for ophthalmic administration
(228.3 nm) with a narrow size distribution (0.156), negatively charged surface (−33.3 mV) and
high EE (∼90%). The in vitro experiments proved that sustained release FB was achieved using NLC as
drug carriers. Optimal NLC formulation did not show toxicity on ocular tissues.